Drug intelligence / Profile preview

rifaximin + bacillus subtilis + enterococcus faecium

Development stage: Preclinical
Lead developer: The Sixth Medical Center of the Chinese People's Liberation Army General Hospital
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

This combination therapy consists of the non-absorbable antibiotic rifaximin and a probiotic mixture containing *Bacillus subtilis* and *Enterococcus faecium*. Rifaximin acts by inhibiting bacterial RNA synthesis through binding to the beta-subunit of bacterial DNA-dependent RNA polymerase, effectively reducing bacterial overgrowth in the small intestine with minimal systemic absorption. The probiotics *Bacillus subtilis* and *Enterococcus faecium* are intended to restore healthy gut microbiota, inhibit the growth of pathogenic bacteria, and improve intestinal barrier function. This therapeutic approach is primarily investigated and used by the Sixth Medical Center of the PLA General Hospital for treating conditions associated with gut dysbiosis, including small intestinal bacterial overgrowth (SIBO), irritable bowel syndrome (IBS), and inflammatory bowel diseases like ulcerative colitis and Crohn's disease. It is also explored for its potential benefits in liver diseases and colorectal health.

Other names: rifaximin and Medilac-S

Targets

rpoB (DNA-directed RNA polymerase subunit beta)

Beyond the preview

Go deeper on rifaximin + bacillus subtilis + enterococcus faecium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rifaximin + bacillus subtilis + enterococcus faecium.

Explore the full profile